FDA Approves Two Separate Indications for fam-Trastuzumab Deruxtecan-nxki in HER2-Positive Early-Stage Breast Cancer By Ogkologos - June 17, 2026 68 0 Facebook Twitter Google+ Pinterest WhatsApp FDA also approved two companion diagnostics for identifying patients for treatment with fam-trastuzumab deruxtecan-nxki Source RELATED ARTICLESMORE FROM AUTHOR Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients with Relapsed Or Refractory Multiple Myeloma FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer Systemic Aging Associated with a Higher Risk of Early-Onset Solid Cancers MOST POPULAR Noninferiority of OS with 3 Months Compared to 6 Months of... January 20, 2026 FDA Approves Avapritinib for Advanced Systemic Mastocytosis June 17, 2021 Understanding Serving Sizes January 15, 2021 In Mouse Study, KRAS-Targeted Drug Shows Potential against Pancreatic Cancer January 12, 2023 Load more HOT NEWS Woman Has Unnecessary Double Mastectomy and Narrowly Avoids Hysterectomy After Bad... Marine Runs Five Marathons in Five Days to Help Fund Sister’s... Two Drugs Work Together to Block ‘Master Regulator’ of Breast, Other... How Your Primary Care Provider Can Help You Throughout Your Cancer...
